BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 19
• 20
• 21
• 22
• 23
• 25
• 26
• 27
• 28

• 

  Drug Development

  Genentech’s Tecentriq Impresses Again in Late-Stage Kidney Cancer Trial

  Genentech said the Phase III combination therapy improved progression-free survival by 26 percent in mRCC patients whose disease expressed a PD-L1 protein.

  February 5, 2018

   · 

  2 min read

   · 

  Alex Keown
• Business

  AbSci Appoints Alan Herman, PhD to Scientific Advisory Board

  AbSci, announced the addition of Coherus’ CSO, Alan Herman, PhD to its Scientific Advisory Board.

  February 5, 2018

   · 

  2 min read
• Biotech Bay

  Abcam and Molecular Devices Announce Strategic Collaboration

  Abcam today announced a strategic collaboration to develop a wide range of fast and reproducible screening tools for researchers.

  February 5, 2018

   · 

  2 min read
• GB Sciences Files a Nonprovisional Patent Application for Cannabis-Based Anti-Inflammatory Therapies Including Arthritis, Asthma, Eczema and More

  The new patent application claims the benefit of GB Sciences’ provisional patent previously filed on February 1, 2017.

  February 5, 2018

   · 

  3 min read
• Lone Star Bio

  NanOlogy to Update Clinical Program Transforming Treatment of Cancer at BIO CEO and Investor Conference

  NanOlogy announced today that Gere diZerega, MD, VP of Medical Affairs, will present at BIO CEO & Investor Conference, February 12, 2018, at 3:15 PM EST in the Brecht room of the New York Marriott Marquis.

  February 5, 2018

   · 

  4 min read
• Business

  BrainStorm Cell Therapeutics Appoints Senior Kite Executive, Anthony Polverino, Ph.D., to Board of Directors

  BrainStorm announced today the appointment of Anthony Polverino, Ph.D., to its board of directors. Dr. Polverino is a highly accomplished senior biopharma executive with more than 25 years’ industry experience in drug research and development.

  February 5, 2018

   · 

  5 min read
• Business

  Encision Reports Third Quarter Fiscal Year 2018 Results

  Encision today announced financial results for its fiscal 2018 third quarter that ended December 31, 2017.

  February 5, 2018

   · 

  16 min read
• Biotech Bay

  Accuray Retires February 2018 Convertible Notes

  Accuray announced today it has retired all February 2018 convertible notes, including $13M aggregate principal amount of its 3.50% convertible senior notes and $27M aggregate principal amount of its 3.50% Series A convertible senior notes both due February 1, 2018.

  February 5, 2018

   · 

  3 min read
• Drug Development

  Tessa Therapeutics Announces Opening of Recruitment Sites Across the United States for its Phase III Nasopharyngeal Cancer Immunotherapy Trial

  The first T cell infusion under the trial in the U.S. was carried out at City of Hope National Medical Center.

  February 5, 2018

   · 

  4 min read
• Pharm Country

  Amneal Launches Methylphenidate Hydrochloride Extended-Release Tablets, USP (CII) AB-Rated Generic for Concerta

  Amneal Pharmaceuticals has launched methylphenidate hydrochloride extended-release tablets, USP in 18, 27, 36, and 54 mg strengths.

  February 5, 2018

   · 

  2 min read